S
0.335
0.01 (1.55%)
| Previous Close | 0.330 |
| Open | 0.330 |
| Volume | 115,136 |
| Avg. Volume (3M) | 421,377 |
| Market Cap | 13,836,371 |
| Price / Sales | 0.660 |
| Price / Book | 0.120 |
| 52 Weeks Range | |
| Earnings Date | 17 Mar 2025 - 23 Mar 2025 |
| Operating Margin (TTM) | -3,453.95% |
| Diluted EPS (TTM) | -1.29 |
| Quarterly Revenue Growth (YOY) | -75.90% |
| Total Debt/Equity (MRQ) | 9.59% |
| Current Ratio (MRQ) | 2.90 |
| Operating Cash Flow (TTM) | -55.96 M |
| Levered Free Cash Flow (TTM) | -38.75 M |
| Return on Assets (TTM) | -47.06% |
| Return on Equity (TTM) | -100.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Spruce Biosciences, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.6
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.63 |
|
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.32% |
| % Held by Institutions | 43.08% |
| 52 Weeks Range | ||
| Median | 0.500 (49.25%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 16 Apr 2025 | 0.500 (49.25%) | Hold | 0.123 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 May 2025 | Announcement | Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |